A Phase 1 Dose Escalation, Safety and Tolerability Study of Jaktinib in Patients With Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) and Who Are Relapsed/ Refractory to a Marketed JAK Inhibitor
Latest Information Update: 26 Mar 2024
At a glance
- Drugs Gecaxitinib hydrochloride (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
Most Recent Events
- 19 Mar 2024 Planned End Date changed from 30 Nov 2023 to 30 Nov 2025.
- 19 Mar 2024 Planned primary completion date changed from 31 May 2023 to 31 May 2025.
- 19 Mar 2024 The planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jul 022 to 1 Jul 2024